138 related articles for article (PubMed ID: 28465540)
1. Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab.
Marisi G; Scarpi E; Passardi A; Nanni O; Ragazzini A; Valgiusti M; Casadei Gardini A; Neri LM; Frassineti GL; Amadori D; Ulivi P
Sci Rep; 2017 May; 7(1):1293. PubMed ID: 28465540
[TBL] [Abstract][Full Text] [Related]
2. eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.
Ulivi P; Scarpi E; Passardi A; Marisi G; Calistri D; Zoli W; Del Re M; Frassineti GL; Tassinari D; Tamberi S; Vertogen B; Amadori D
J Transl Med; 2015 Aug; 13():258. PubMed ID: 26259598
[TBL] [Abstract][Full Text] [Related]
3. Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy.
Ulivi P; Scarpi E; Chiadini E; Marisi G; Valgiusti M; Capelli L; Casadei Gardini A; Monti M; Ruscelli S; Frassineti GL; Calistri D; Amadori D; Passardi A
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28598398
[TBL] [Abstract][Full Text] [Related]
4. IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.
Di Salvatore M; Pietrantonio F; Orlandi A; Del Re M; Berenato R; Rossi E; Caporale M; Guarino D; Martinetti A; Basso M; Mennitto R; Santonocito C; Mennitto A; Schinzari G; Bossi I; Capoluongo E; Danesi R; de Braud F; Barone C
Oncotarget; 2017 Mar; 8(10):16887-16898. PubMed ID: 28129643
[TBL] [Abstract][Full Text] [Related]
5. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
[TBL] [Abstract][Full Text] [Related]
6. Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer.
Marisi G; Azzali I; Passardi A; Rebuzzi F; Bartolini G; Urbini M; Canale M; Molinari C; Matteucci L; Sullo FG; Debonis SA; Gallio C; Gallo G; Frassineti GL; Ulivi P
Sci Rep; 2023 Aug; 13(1):12921. PubMed ID: 37558720
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).
Avallone A; Piccirillo MC; Aloj L; Nasti G; Delrio P; Izzo F; Di Gennaro E; Tatangelo F; Granata V; Cavalcanti E; Maiolino P; Bianco F; Aprea P; De Bellis M; Pecori B; Rosati G; Carlomagno C; Bertolini A; Gallo C; Romano C; Leone A; Caracò C; de Lutio di Castelguidone E; Daniele G; Catalano O; Botti G; Petrillo A; Romano GM; Iaffaioli VR; Lastoria S; Perrone F; Budillon A
BMC Cancer; 2016 Feb; 16():69. PubMed ID: 26857924
[TBL] [Abstract][Full Text] [Related]
8. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
[TBL] [Abstract][Full Text] [Related]
9. Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
Ulivi P; Canale M; Passardi A; Marisi G; Valgiusti M; Frassineti GL; Calistri D; Amadori D; Scarpi E
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29361687
[TBL] [Abstract][Full Text] [Related]
10. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
[TBL] [Abstract][Full Text] [Related]
11. Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
Passardi A; Scarpi E; Tamberi S; Cavanna L; Tassinari D; Fontana A; Pini S; Bernardini I; Accettura C; Ulivi P; Frassineti GL; Amadori D
PLoS One; 2015; 10(8):e0134732. PubMed ID: 26244985
[TBL] [Abstract][Full Text] [Related]
12. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial.
Pineda E; Salud A; Vila-Navarro E; Safont MJ; Llorente B; Aparicio J; Vera R; Escudero P; Casado E; Bosch C; Bohn U; Pérez-Carrión R; Carmona A; Ayuso JR; Ripollés T; Bouzas R; Gironella M; García-Albéniz X; Feliu J; Maurel J
Tumour Biol; 2017 Jun; 39(6):1010428317705509. PubMed ID: 28621236
[TBL] [Abstract][Full Text] [Related]
13. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
14. Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab.
Hegde PS; Jubb AM; Chen D; Li NF; Meng YG; Bernaards C; Elliott R; Scherer SJ; Chen DS
Clin Cancer Res; 2013 Feb; 19(4):929-37. PubMed ID: 23169435
[TBL] [Abstract][Full Text] [Related]
15. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
16. Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients.
Suenaga M; Cao S; Zhang W; Yang D; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Schirripa M; Soni S; Barzi A; Yamaguchi T; Lenz HJ
Int J Cancer; 2019 May; 144(10):2567-2577. PubMed ID: 30411783
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
18.
Papachristos A; Kemos P; Katsila T; Panoilia E; Patrinos GP; Kalofonos H; Sivolapenko GB
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752122
[TBL] [Abstract][Full Text] [Related]
19. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
20. Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study.
Baba H; Baba Y; Uemoto S; Yoshida K; Saiura A; Watanabe M; Maehara Y; Oki E; Ikeda Y; Matsuda H; Yamamoto M; Shimada M; Taketomi A; Unno M; Sugihara K; Ogata Y; Eguchi S; Kitano S; Shirouzu K; Saiki Y; Takamori H; Mori M; Hirata T; Wakabayashi G; Kokudo N
Oncotarget; 2015 Oct; 6(32):34004-13. PubMed ID: 26372896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
